This systematic review evaluated 35 randomized controlled trials assessing the efficacy and safety of ketamine in treating Major Depressive Disorder (MDD). Intravenous (IV) ketamine demonstrated significant antidepressant effects in 70% of the studies, while oral and intranasal routes showed limited efficacy. Common adverse effects included nausea, vomiting, dizziness, diplopia, drowsiness,
